The present invention relates to a new therapeutic indication of known derivatives of phenytoin or a stable pharmaceutical composition of the phenytoin prodrug which is now known as fosphenytoin sodium. More particularly, the present invention concerns a method of preparing pharmaceutical compositions for treating cerebral ischemia or stroke in a human by using the derivatives of phenytoin, preferably 3-(hydroxy-methyl)-5,5-diphenylhydantoin phosphate ester disodium salt or a prodrug of phenytoin as active compounds. The preferred compound is also variously known as the fosphenytoin sodium; 5,5-diphenyl-3-[(phosphonooxy)methyl]-2,4-imidazolidinedione disodium salt; 3-phosphoryl-oxymethyl-5,5-diphenylhydantoin disodium salt; or 3-(hydroxymethyl)-5,5-diphenylhydantoin disodium phosphate ester
本发明涉及一种已知
苯妥英衍
生物或
苯妥英原药(现称为
磷苯妥英钠)的稳定药物组合物的新治疗适应症。更具体地说,本发明涉及一种使用
苯妥英衍
生物,优选 3-(羟甲基)-5,5-二苯基海因
磷酸酯二钠盐或
苯妥英原药作为活性化合物,制备治疗人类脑缺血或中风的药物组合物的方法。优选的化合物也被称为
磷苯妥英钠;5,5
-二苯基-3-[(
磷酰氧基)甲基]-2,4-
咪唑烷二酮二钠盐;3-
磷酰-氧甲基-5,5-二苯基海因二钠盐;或 3-(羟甲基)-5,5-二苯基海因
磷酸酯二钠盐。